Accession Number: | 0001209191-20-010541 |
Date: | 2020-02-17 |
Issuer: | VERTEX PHARMACEUTICALS INC / MA (VRTX) |
Original Submission Date: |
KEWALRAMANI RESHMA
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON, MA 02210
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2020-02-17 | F | 944 | d | $241.50 | 34,341 | direct | ||
COMMON STOCK | 2020-02-18 | S | 120 | d | $241.71 | 34,221 | direct | ||
COMMON STOCK | 2020-02-18 | S | 540 | d | $242.62 | 33,681 | direct | ||
COMMON STOCK | 2020-02-18 | S | 134 | d | $243.76 | 33,547 | direct | ||
COMMON STOCK | 2020-02-18 | S | 260 | d | $244.94 | 33,287 | direct | ||
COMMON STOCK | 2020-02-18 | S | 129 | d | $245.75 | 33,158 | direct |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|
ID | footnote |
---|---|
f1 | transaction made pursuant to dr. kewalramani's company approved trading plan under rule 10b5-1. |
f2 | open market sales reported on this line occurred at a weighted average price of $241.71 (range $241.24 to $242.02). |
f3 | dr. kewalramani undertakes to provide (upon request by the sec staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
f4 | open market sales reported on this line occurred at a weighted average price of $242.62 (range $242.25 to $243.21). |
f5 | open market sales reported on this line occurred at a weighted average price of $243.76 (range $243.25 to $244.08). |
f6 | open market sales reported on this line occurred at a weighted average price of $244.94 (range $244.36 to $245.32). |
f7 | open market sales reported on this line occurred at a weighted average price of $245.75 (range $245.36 to $245.86). |